Canada’s Controversial Pricing Guidelines Suspended
Executive Summary
The implementation of new pricing guidelines that are unpopular with the pharmaceutical has been put on hold, to the relief of the pharmaceutical industry.
You may also be interested in...
Canada Tackles Pricing Review Backlog With New Interim Guidance
Canada’s Patented Medicine Prices Review Board is consulting on further draft interim guidance on pricing to expedite reviews of medicines authorized since July 2022.
Canadian Court Upholds New Drug Price Comparison Basket – With Caveats
A Canadian court has dismissed an appeal brought by industry challenging new pricing rules that introduce a revised basket of reference countries as part of cost-containment measures.
Industry Calls For Canadian Pricing Guideline Consultation To Be Suspended
IMC, the R&D-based pharmaceutical industry association in Canada, says the guideline will “exacerbate an already unpredictable regulatory environment.”